To the Editor Dr Bach,1 in discussing indication-specific pricing for cancer drugs, examined the practical aspects of linking the price of a drug to its benefits. However, he did not mention the Italian experience in this area, which extends more than 5 years2,3 and involves a total of 162 agents, most of which are oncological drugs.
Messori A, De Rosa M, Pani L. Alternative Pricing Strategies for Cancer Drugs. JAMA. 2015;313(8):857. doi:10.1001/jama.2014.17814